WO1997038711A3 - T-cell dependent vaccine and the cell surface receptor cd28 - Google Patents

T-cell dependent vaccine and the cell surface receptor cd28 Download PDF

Info

Publication number
WO1997038711A3
WO1997038711A3 PCT/GB1997/000971 GB9700971W WO9738711A3 WO 1997038711 A3 WO1997038711 A3 WO 1997038711A3 GB 9700971 W GB9700971 W GB 9700971W WO 9738711 A3 WO9738711 A3 WO 9738711A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
surface receptor
cell surface
vaccine
dependent vaccine
Prior art date
Application number
PCT/GB1997/000971
Other languages
French (fr)
Other versions
WO1997038711A2 (en
Inventor
Andrew William Heath
Original Assignee
Univ Sheffield
Andrew William Heath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield, Andrew William Heath filed Critical Univ Sheffield
Priority to AU23031/97A priority Critical patent/AU2303197A/en
Priority to EP97915616A priority patent/EP0909179A2/en
Publication of WO1997038711A2 publication Critical patent/WO1997038711A2/en
Publication of WO1997038711A3 publication Critical patent/WO1997038711A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a novel vaccine suitable for enhancing T-cell dependent immunity comprising a T-cell dependent antigen, such as a soluble protein, and an associated adjuvant, the adjuvant being adapted to stimulate a T-cell lymphocyte via the cell surface receptor CD28.
PCT/GB1997/000971 1996-04-13 1997-04-08 T-cell dependent vaccine and the cell surface receptor cd28 WO1997038711A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU23031/97A AU2303197A (en) 1996-04-13 1997-04-08 T-cell dependent vaccine and the cell surface receptor cd28
EP97915616A EP0909179A2 (en) 1996-04-13 1997-04-08 T-cell dependent vaccine and the cell surface receptor cd28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9607711.0 1996-04-13
GBGB9607711.0A GB9607711D0 (en) 1996-04-13 1996-04-13 T-cell dependent vaccine

Publications (2)

Publication Number Publication Date
WO1997038711A2 WO1997038711A2 (en) 1997-10-23
WO1997038711A3 true WO1997038711A3 (en) 1997-11-20

Family

ID=10792036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000971 WO1997038711A2 (en) 1996-04-13 1997-04-08 T-cell dependent vaccine and the cell surface receptor cd28

Country Status (4)

Country Link
EP (1) EP0909179A2 (en)
AU (1) AU2303197A (en)
GB (1) GB9607711D0 (en)
WO (1) WO1997038711A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011833B1 (en) 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods
WO1993019767A1 (en) * 1992-04-07 1993-10-14 The Regents Of The University Of Michigan Cd28 pathway immunoregulation
DE4407538C1 (en) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Binding reagent for cell surface protein and effector cell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods
WO1993019767A1 (en) * 1992-04-07 1993-10-14 The Regents Of The University Of Michigan Cd28 pathway immunoregulation
DE4407538C1 (en) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Binding reagent for cell surface protein and effector cell

Also Published As

Publication number Publication date
AU2303197A (en) 1997-11-07
GB9607711D0 (en) 1996-06-19
EP0909179A2 (en) 1999-04-21
WO1997038711A2 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
AU7182591A (en) Soluble t-cell antigen receptor chimeric antigens
EP1014787A4 (en) Adjuvant for transcutaneous immunization
ZA964614B (en) Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates.
BG101995A (en) Saponin and sterol-containing vaccines
AU8036898A (en) Soi substrate and process for preparing the same, and semiconductor device and process for preparing the same
AU3989297A (en) Hyper-text document preparing apparatus
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
WO1998050547A3 (en) Human toll-like receptor proteins, related reagents and methods
MX9707021A (en) Il-17 receptor.
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU4070097A (en) Mucosal immunogens for novel vaccines
AU1652197A (en) Novel estrogen receptor
AU7983198A (en) Improved methods for inducing an immune response
EP0866133A3 (en) A group b streptococcus vaccine
AU6941698A (en) Anti-cancer vaccine
AU5506896A (en) Human p2x4 receptor splice-variants
AU5931698A (en) Universal t-cell epitopes for anti-malarial vaccines
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
AU2292800A (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides andprotective antibodies
WO1997038711A3 (en) T-cell dependent vaccine and the cell surface receptor cd28
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO2003051305A3 (en) Innate immune system-directed vaccines
AU4990999A (en) Survivin, and peptides thereof, as an anti-cancer vaccine
GB2310667B (en) Methods for the preparation of polyborosiloxanes and of silicon and boron oxynitrides,and polyborosiloxanes and silicon and boron oxynitrides obtained thereby

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997915616

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536832

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997915616

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997915616

Country of ref document: EP